GERN
Geron Corporation
$1.43
-0.02
(-1.04%)
Mkt Cap
923.79M
Volume
675,119
52W Range
1.04-2.01
Sector
Healthcare
Beta
0.60
EPS (TTM)
-0.10
P/E Ratio
-10.15
Revenue (TTM)
196.12M
Rev Growth (5Y)
+273.6%
EPS Growth (5Y)
N/A
Company Description
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 183.88M | 76.99M | 237,000 | 596,000 | 1.39M | 253,000 | 460,000 | 1.07M | 1.06M | 6.16M | 36.37M | 1.15M |
| Net Income | (85.78M) | (174.57M) | (184.13M) | (141.90M) | (116.11M) | (75.62M) | (68.55M) | (27.02M) | (27.92M) | (29.54M) | 46,000 | (35.67M) |
| EPS | -0.13 | -0.27 | -0.32 | -0.37 | -0.37 | -0.28 | -0.33 | -0.15 | -0.18 | -0.19 | 0.00 | -0.23 |
| Free Cash Flow | (111.09M) | (219.30M) | (168.57M) | (127.81M) | (95.76M) | (67.05M) | (44.24M) | (21.02M) | (20.56M) | (18.43M) | (24.29M) | 9.22M |
| FCF / Share | -0.17 | -0.34 | -0.30 | -0.34 | -0.29 | -0.25 | -0.23 | -0.12 | -0.13 | -0.12 | -0.15 | 0.06 |
| Operating CF | (111.04M) | (218.62M) | (167.74M) | (127.38M) | (95.56M) | (66.65M) | (43.83M) | (21.01M) | (20.56M) | (18.37M) | (24.20M) | 9.35M |
| Total Assets | 570.54M | 593.78M | 394.08M | 190.57M | 226.03M | 270.73M | 165.52M | 185.28M | 110.31M | 130.25M | 148.76M | 172.51M |
| Total Debt | 251.57M | 121.72M | 85.90M | 55.75M | 55.00M | 29.72M | 2.55M | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 79.44M | 79.02M | 70.02M | 56.84M | 34.87M | 9.93M | 13.64M | 10.84M | 16.60M | 13.08M | 21.52M | 43.06M |
| Book Value | 225.87M | 280.32M | 247.95M | 80.00M | 126.42M | 210.95M | 135.16M | 177.73M | 103.80M | 122.38M | 142.13M | 130.71M |
| Return on Equity | -0.38 | -0.62 | -0.74 | -1.77 | -0.92 | -0.36 | -0.51 | -0.15 | -0.27 | -0.24 | 0.00 | -0.27 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.84M | 48.02M | 47.23M | 49.04M | 39.60M | 47.54M | 28.27M | 882,000 | 304,000 | 23,000 | 164,000 | 29,000 |
| Net Income | (3.64M) | (31.14M) | (18.43M) | (16.38M) | (19.84M) | (25.35M) | (26.45M) | (67.38M) | (55.39M) | (51.97M) | (44.80M) | (49.23M) |
| EPS | -0.01 | -0.05 | -0.03 | -0.02 | -0.03 | -0.04 | -0.04 | -0.10 | -0.09 | -0.09 | -0.08 | -0.09 |
| Free Cash Flow | (63.16M) | (22.10M) | (13.49M) | (27.55M) | (47.98M) | (43.80M) | (58.94M) | (53.68M) | (62.87M) | (41.00M) | (51.03M) | (29.80M) |
| FCF / Share | -0.09 | -0.03 | -0.02 | -0.04 | -0.07 | -0.07 | -0.09 | -0.08 | -0.10 | -0.07 | -0.09 | -0.05 |
| Operating CF | (62.91M) | (22.07M) | (13.58M) | (27.41M) | (47.98M) | (43.95M) | (58.94M) | (53.48M) | (62.25M) | (40.94M) | (50.84M) | (29.60M) |
| Total Assets | 534.12M | 570.54M | 567.38M | 555.20M | 562.45M | 593.78M | 444.95M | 449.40M | 482.07M | 394.08M | 413.02M | 415.30M |
| Total Debt | 251.84M | 251.57M | 121.92M | 121.84M | 121.78M | 121.72M | 87.26M | 87.04M | 86.53M | 85.90M | 56.02M | 55.93M |
| Cash & Equiv | 70.78M | 79.44M | 78.12M | 77.73M | 83.75M | 79.02M | 60.34M | 116.94M | 189.76M | 71.14M | 30.71M | 56.90M |
| Book Value | 229.11M | 225.87M | 248.71M | 259.53M | 268.24M | 280.32M | 292.28M | 306.69M | 344.87M | 247.95M | 290.61M | 298.43M |
| Return on Equity | -0.02 | -0.14 | -0.07 | -0.06 | -0.07 | -0.09 | -0.09 | -0.22 | -0.16 | -0.21 | -0.15 | -0.16 |
GERN News
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
Geron Corporation: Commercial Performance Could Dovetail With IMpactMF Run-Up
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN)
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Geron: Time To Reconsider This Oversold Biotech
Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner